JP2005102701A5 - - Google Patents

Download PDF

Info

Publication number
JP2005102701A5
JP2005102701A5 JP2004338711A JP2004338711A JP2005102701A5 JP 2005102701 A5 JP2005102701 A5 JP 2005102701A5 JP 2004338711 A JP2004338711 A JP 2004338711A JP 2004338711 A JP2004338711 A JP 2004338711A JP 2005102701 A5 JP2005102701 A5 JP 2005102701A5
Authority
JP
Japan
Prior art keywords
amino acid
pharmaceutical composition
antigenic
acid residues
ige
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004338711A
Other languages
English (en)
Other versions
JP2005102701A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2005102701A publication Critical patent/JP2005102701A/ja
Publication of JP2005102701A5 publication Critical patent/JP2005102701A5/ja
Pending legal-status Critical Current

Links

Claims (15)

  1. 配列番号:8又は配列番号:11のアミノ酸配列を含んでなる、又はそのフラグメントである、抗原性ペプチド。
  2. 異種担体タンパク質に連結された請求項1に記載の抗原性ペプチドを含んでなる、抗原性融合タンパク質。
  3. 医薬担体の一以上、及び免疫原的に有効な量の請求項1に記載の抗原性ペプチドの一以上を含む、医薬組成物。
  4. 医薬担体の一以上、及び請求項2に記載の抗原性融合タンパク質の一以上を含む、医薬組成物。
  5. 請求項3又は4に記載の医薬組成物であって、フラグメントが、少なくとも5アミノ酸残基長、少なくとも10アミノ酸残基長、少なくとも15アミノ酸残基長、少なくとも20アミノ酸残基長、少なくとも25アミノ酸残基長、又は少なくとも30アミノ酸残基長である、医薬組成物。
  6. さらにアジュバントを含む、請求項3〜5のいずれか1項に記載の医薬組成物。
  7. IgE介在性アレルギー障害の治療又は予防のための、請求項3〜6のいずれか1項に記載の医薬組成物。
  8. IgE介在性アレルギー障害の治療又は予防のための医薬の製造のための、請求項3〜6のいずれか1項に記載の医薬組成物の使用。
  9. IgE介在性アレルギー障害が、喘息、アレルギー性鼻炎、胃腸のアレルギー、食物アレルギー、好酸球増加症、結膜炎、糸球体腎炎及び移植片対宿主病からなる群より選択される、請求項7に記載の医薬組成物又は請求項8に記載の使用。
  10. 請求項1に記載の抗原性ペプチド又は請求項2に記載の抗原性融合タンパク質をコードする、ポリヌクレオチド。
  11. 請求項10に記載のポリヌクレオチドを含む発現ベクターを包含する、宿主細胞。
  12. 配列番号:22又は配列番号:25のポリヌクレオチド配列を含んでなる、ポリヌクレオチド。
  13. 請求項1に記載の抗原性ペプチド又は請求項2に記載の抗原性融合タンパク質を製造する方法であって、請求項11に記載の宿主細胞の培養物を好適な培地で増殖させ、そして培養物からペプチド又はタンパク質を精製する、製造方法。
  14. IgE介在性アレルギー障害の治療又は予防方法であって、そのような治療又は予防が所望される非ヒト動物へ、免疫原的に有効な量の請求項1に記載の抗原性ペプチド又は請求項2に記載の抗原性融合タンパク質を投与することを含む、方法。
  15. IgE介在性アレルギー障害の治療又は予防方法であって、そのような治療又は予防が所望される非ヒト動物へ、免疫原的に有効な量の請求項10に記載のポリヌクレオチドを投与することを含む、方法。
JP2004338711A 2000-08-30 2004-11-24 抗IgEワクチン Pending JP2005102701A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22898900P 2000-08-30 2000-08-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2001261760A Division JP2002281984A (ja) 2000-08-30 2001-08-30 抗IgEワクチン

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012080895A Division JP2012161322A (ja) 2000-08-30 2012-03-30 抗IgEワクチン

Publications (2)

Publication Number Publication Date
JP2005102701A JP2005102701A (ja) 2005-04-21
JP2005102701A5 true JP2005102701A5 (ja) 2011-04-21

Family

ID=22859366

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2001261760A Pending JP2002281984A (ja) 2000-08-30 2001-08-30 抗IgEワクチン
JP2004244935A Pending JP2005043374A (ja) 2000-08-30 2004-08-25 抗IgEワクチン
JP2004338711A Pending JP2005102701A (ja) 2000-08-30 2004-11-24 抗IgEワクチン
JP2012080895A Pending JP2012161322A (ja) 2000-08-30 2012-03-30 抗IgEワクチン
JP2012232974A Pending JP2013056904A (ja) 2000-08-30 2012-10-22 抗IgEワクチン

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2001261760A Pending JP2002281984A (ja) 2000-08-30 2001-08-30 抗IgEワクチン
JP2004244935A Pending JP2005043374A (ja) 2000-08-30 2004-08-25 抗IgEワクチン

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2012080895A Pending JP2012161322A (ja) 2000-08-30 2012-03-30 抗IgEワクチン
JP2012232974A Pending JP2013056904A (ja) 2000-08-30 2012-10-22 抗IgEワクチン

Country Status (4)

Country Link
US (5) US6887472B2 (ja)
EP (5) EP2361635A3 (ja)
JP (5) JP2002281984A (ja)
CA (5) CA2674885C (ja)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887472B2 (en) * 2000-08-30 2005-05-03 Pfizer Inc. Anti-IgE vaccines
EP2330187B1 (en) * 2001-05-15 2016-07-27 Janssen Pharmaceuticals, Inc. CD8+ T cells specific for peptide WVDNKTFSV that are specifically cytotoxic for IgE-positive target cells and methods of production.
JP2003047482A (ja) * 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性IgEワクチン
ES2316780T3 (es) * 2002-09-05 2009-04-16 Resistentia Pharmaceuticals Ab Vacunas contra alergia.
US9320792B2 (en) 2002-11-08 2016-04-26 Ablynx N.V. Pulmonary administration of immunoglobulin single variable domains and constructs thereof
US20100003253A1 (en) * 2002-11-08 2010-01-07 Ablynx N.V. Single domain antibodies directed against epidermal growth factor receptor and uses therefor
US20060034845A1 (en) * 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
CA2505326A1 (en) * 2002-11-08 2004-05-21 Ablynx N.V. Camelidae antibodies against immunoglobulin e and use thereof for the treatment of allergic disorders
PT2316852E (pt) * 2002-11-08 2014-06-23 Ablynx Nv Anticorpos de domínio único estáveis
KR101365375B1 (ko) 2004-02-02 2014-02-19 타녹스 인코퍼레이티드 신규한 IgE 에피토프의 확인
JP4520923B2 (ja) * 2005-09-28 2010-08-11 本田技研工業株式会社 エンジン始動装置
JP2007172129A (ja) * 2005-12-20 2007-07-05 Sony Corp 不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム
AU2013204233B2 (en) * 2008-12-09 2015-06-25 Pfizer Vaccines Llc IgE CH3 peptide vaccine
KR101644221B1 (ko) * 2008-12-09 2016-07-29 화이자 백신스 엘엘씨 IgE CH3 펩티드 백신
EP2401300B1 (en) * 2009-02-25 2018-01-10 Academia Sinica ANTI-C[epsilon]mX ANTIBODIES CAPABLE OF BINDING TO HUMAN mIgE ON B LYMPHOCYTES
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
KR101163472B1 (ko) * 2010-06-08 2012-07-18 기아자동차주식회사 자동차의 오프닝 웨더스트립 고정구조
US9187553B2 (en) * 2012-01-25 2015-11-17 Swey-Shen Chen Displaying native human IgE neutralizing FcepsilonRIa-contacting IgE B-cell epitopes by constraining super beta(b)-strands and cystine knots on thermostable protein scaffold
US9587034B2 (en) 2012-04-20 2017-03-07 Academia Sinica Anti-mIgE antibodies that bind to the junction between CH4 and CεmX domains
CN102660569B (zh) * 2012-04-21 2013-11-06 大连理工大学 一种重组人IgE受体蛋白的制备方法及应用
JP5918851B2 (ja) * 2012-06-18 2016-05-18 日本全薬工業株式会社 IgEペプチドワクチン
JP6739702B2 (ja) * 2014-06-11 2020-08-12 国立研究開発法人理化学研究所 多重同種抗原ペプチド
WO2016164920A1 (en) * 2015-04-09 2016-10-13 Cornell University Gene therapy to prevent reactions to allergens
AU2018360999A1 (en) 2017-10-31 2020-05-14 Oneness Biotech Co. Ltd. Treating IgE-mediated allergic diseases
US11857623B2 (en) * 2020-08-07 2024-01-02 King Abdulaziz University Pan-antiallergy vaccine
EP4431528A1 (en) * 2021-10-29 2024-09-18 Longbio Pharma (Suzhou) Co., Ltd. Isolated antigen binding protein and use thereof
CN115873867B (zh) * 2022-09-28 2023-06-23 云南省农业科学院农业环境资源研究所 一种抗稻瘟病基因Pi69及其编码蛋白与应用
CN116143932A (zh) * 2022-12-07 2023-05-23 南开大学 一种针对IgE的抗体或其抗原结合片段以及Fc变体

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
JPS5668615A (en) * 1979-11-09 1981-06-09 Eisai Co Ltd Ricin-containing agent for immunological enhancement
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
GB8616166D0 (en) * 1986-07-02 1986-08-06 Research Corp Ltd Polypeptide competitor
JPS63225397A (ja) 1986-10-03 1988-09-20 Dainippon Pharmaceut Co Ltd 抗アレルギー作用を有する新規ペプチド
GB8913737D0 (en) 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
WO1992006180A1 (en) 1990-10-01 1992-04-16 University Of Connecticut Targeting viruses and cells for selective internalization by cells
ES2154637T3 (es) 1991-05-14 2001-04-16 Univ Connecticut Aportacion de genes dirigidos que codifican proteinas inmunogenicas.
AU657345B2 (en) 1991-05-24 1995-03-09 Northwestern University Method of using substance P to treat allergy
ATE195656T1 (de) 1991-06-05 2000-09-15 Univ Connecticut Zielgerichtete freisetzung von genen, die sekretorische proteine kodieren
US5965709A (en) * 1991-08-14 1999-10-12 Genentech, Inc. IgE antagonists
SE9102808L (sv) * 1991-09-26 1993-03-27 Lars T Hellman Inst F Immunolo Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner
AU3434393A (en) 1992-01-17 1993-08-03 Regents Of The University Of Michigan, The Targeted virus
CA2133411A1 (en) 1992-04-03 1993-10-14 Alexander T. YOUNG Gene therapy using targeted viral vectors
ES2157225T3 (es) 1992-10-09 2001-08-16 Advanced Tissue Sciences Inc Celulas hepaticas de reserva.
EP0905253A3 (en) 1992-12-03 2000-11-02 Genzyme Corporation Adenoviral vector deleted of all E4-ORF except ORF6
GB9324013D0 (en) * 1993-11-22 1994-01-12 3I Res Expl Ltd Polypeptides
FR2715304B1 (fr) * 1994-01-26 1996-04-26 Merieux Serums Vaccins Pasteur Vaccin anti-allergique.
US5629415A (en) * 1994-11-09 1997-05-13 Merck & Co., Inc. DNA encoding canine immunoglobulin E
JPH09169795A (ja) * 1995-12-22 1997-06-30 Hitachi Chem Co Ltd イヌ免疫グロブリンeペプチド断片、それをコードするdna、そのdnaを含む組換えベクター、その組換えベクターを含む形質転換体及び抗イヌ免疫グロブリンe抗体の製造法
WO1997030156A2 (en) 1996-02-14 1997-08-21 Idexx Laboratories, Inc. NUCLEOTIDES AND PEPTIDES CORRESPONDING TO THE CANINE IgE HEAVY CHAIN CONSTANT REGION AND RELATED METHODS
DE69718150T3 (de) 1996-03-01 2009-03-05 Novartis Ag Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien
JP2000517321A (ja) 1996-08-30 2000-12-26 エクソン・ケミカル・パテンツ・インク 流動床反応器及び流動床方法
AU6532498A (en) 1996-12-06 1998-06-29 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Inhibition of ige-mediated allergies by a human ige-derived oligopeptide
US6734287B1 (en) * 1998-04-09 2004-05-11 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
EP0957111B1 (en) * 1998-04-09 2004-12-29 Idexx Laboratories, Inc. Specific binding proteins for treating canine allergy
TWI229679B (en) * 1998-06-20 2005-03-21 United Biomedical Inc Artificial T helper cell epitopes as immune stimulators for synthetic peptide immunogens
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
ATE403866T1 (de) * 1998-06-24 2008-08-15 Alk Abello As Verfahren zum nachweis von antikörpern in flüssigen proben
GB9822763D0 (en) * 1998-10-20 1998-12-16 Univ Sheffield Immunoglobin variant
US6913749B2 (en) * 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
CN1202125C (zh) * 1998-11-12 2005-05-18 卫生部上海生物制品研究所 肽免疫原、用其制成的治疗变态反应的疫苗及其制备方法
US6887472B2 (en) 2000-08-30 2005-05-03 Pfizer Inc. Anti-IgE vaccines
JP2003047482A (ja) 2001-05-22 2003-02-18 Pfizer Prod Inc 非アナフィラキシー誘発性IgEワクチン

Similar Documents

Publication Publication Date Title
JP2005102701A5 (ja)
US11479880B2 (en) Fibronectin type III domain based scaffold compositions, methods and uses
AU2010213892B2 (en) Fibronectin type III domain based scaffold compositions, methods and uses
US8415291B2 (en) Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses
JP2015164424A5 (ja)
JP2009507474A5 (ja)
RU2009119925A (ru) Il-18 вакцина для лечения различных воспалительных состояний
RU2007127921A (ru) Вакцины и их применение
JP2005502327A5 (ja)
RU2007108037A (ru) Фармацевтическая композиция для лечения гепатита с на основе неинфекционных псевдовирионов вируса гепатита с